Table 1.
Patient demographics and disease characteristics
| 1.0 mg/kg q2w (Group 1, n = 4) | 3.0 mg/kg q2w (Group 2, n = 4) | 10 mg/kg q2w (Group 3, n = 4) | 15 mg/kg q3w (Group 4, n = 6) | 20 mg/kg q4w (Group 5, n = 4) | Total (N = 22) | |
|---|---|---|---|---|---|---|
| Median age, y (range) | 53.5 (42‐68) | 57.0 (45‐76) | 68.5 (66‐75) | 62.0 (48‐72) | 61.5 (41‐66) | 61.5 (41‐76) |
| Gender, n (%) | ||||||
| Male | 1 (25) | 4 (100) | 3 (75) | 2 (33) | 4 (100) | 14 (64) |
| Female | 3 (75) | 0 | 1 (25) | 4 (67) | 0 | 8 (36) |
| ECOG performance status, n (%) | ||||||
| 0 | 2 (50) | 2 (50) | 3 (75) | 4 (67) | 2 (50) | 13 (59) |
| 1 | 2 (50) | 2 (50) | 1 (25) | 2 (33) | 2 (50) | 9 (41) |
| Median no. of prior chemotherapies, n (range) | 3.0 (1‐5) | 3.0 (1‐5) | 2.0 (1‐5) | 3.5 (2‐5) | 3.5 (0‐6) | 3.0 (0‐6) |
| Tumor type, n (%) | ||||||
| Gastric/gastroesophageal | 0 | 1 (25) | 1 (25) | 1 (17) | 1 (25) | 4 (18) |
| NSCLC | 1 (25) | 1 (25) | 2 (50) | 0 | 0 | 3 (14) |
| Cervical cancer | 2 (50) | 0 | 0 | 0 | 0 | 2 (9) |
| Ovarian cancer | 1 (25) | 0 | 0 | 1 (17) | 0 | 2 (9) |
| Malignant melanoma | 1 (25) | 0 | 1 (25) | 0 | 0 | 2 (9) |
| Breast cancer | 0 | 0 | 0 | 1 (17) | 0 | 1 (5) |
| Thyroid cancer | 0 | 1 (25) | 0 | 0 | 0 | 1 (5) |
| Othera | 0 | 1 (25) | 0 | 3 (50) | 3 (75) | 7 (32) |
CR, complete response; NSCLC, non–small‐cell lung cancer; PD, progressive disease; PR, partial response; q2w, every 2 weeks; q3w, every 3 weeks; q4w, every 4 weeks; SD, stable disease.
a
Urachal carcinoma, lung adenocarcinoma, intrahepatic bile duct carcinoma, pancreatic cancer, hypopharyngeal cancer, thymic cancer, and cancer of unknown primary.